When we think of the biopharmaceutical industry, we naturally think of innovation in terms of discovery of novel medicines treating any number of diseases and conditions. The innovation occurring in the pharma industry isn't limited to drug discovery, and has also extended into the application of technology in pursuit of developing new therapies. In this episode, we dive into how the pharma industry thinks through the development and deployment of novel technology. Technologies such as clinical operations software, AI, and machine learning have increased the efficiency of every stage of the drug development process. This embrace has helped drive the discovery of new therapeutic classes and the development of drugs for targets and diseases that were previously thought untreatable. To discuss this topic, we're joined by Shobie Ramakrishnan, GSK's Chief Digital and Technology Officer. Since joining GSK in 2018, she has transformed the company’s capabilities in digital, data, and analytics, and has played a pivotal role in establishing a more agile commercial operating model. Before joining GSK, Shobie held senior technology leadership roles in organizations including AstraZeneca, Salesforce, Genentech, and Roche.

https://go.td.com/PodcastDisclosure